Continue to Site

Ultra Supplement announces recall for undeclared tadalafil

By Brian Buntz | July 26, 2022

The FDA continues to pressure manufacturers and distributors for selling products with undeclared sildenafil and tadalafil.

The agency recently announced that Wilmington Delaware–based Ultra Supplement LLC is voluntarily recalling lot number DAP272109 of Sustango capsules over the presence of tadalafil (Cialis).

The company markets the product as a supplement for men. Sustango was available for sale on Amazon.

Amazon had notified Ultra Supplement that the product appeared to be tainted with the PDE-5 inhibitor tadalafil based on laboratory analysis.

Earlier this week, FDA warned four companies over selling honey tainted with tadalafil and sildenafil.

FDA notes that consumers with a heart condition, diabetes and high blood pressure who take nitrates should avoid PDE-5 inhibitors as they may lead to dangerous blood pressure drops.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.